Oxurion Receives Transparency Notifications from Atlas (NYSE:) Particular Alternatives LLC
Leuven, BELGIUM “ April 11, 2024 “ 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical firm headquartered in Leuven, in the present day introduced that, pursuant to Belgian Transparency legislation1 it has obtained two transparency notifications as follows:
Oxurion obtained a primary transparency notification on April 10, 2024, from Atlas Particular Alternatives, LLC indicating that as of April 1, 2024, it held 1,630,434,782 shares of the then excellent 9,014,821,287 shares, and due to this fact crossed above the edge (15%) by advantage of the acquisition of securities. See Annex 1.
Oxurion obtained a second transparency notification on April 10, 2024, from Atlas Particular Alternatives, LLC indicating that as of April 8, 2024, it held 886,039,886 shares of the then excellent 9,014,821,287 shares, and due to this fact crossed beneath the edge (10%) by advantage of the sale of securities. See Annex 2.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in creating next-generation normal of care ophthalmic therapies for the remedy of retinal illness. Oxurion is predicated in Leuven, Belgium. Extra info is out there at www.oxurion.com.
Necessary details about forward-looking statements
Sure statements on this press launch could also be thought-about forward-looking. Such forward-looking statements are based mostly on present expectations, and, accordingly, entail and are influenced by varied dangers and uncertainties. The Firm due to this fact can not present any assurance that such forward-looking statements will materialize and doesn’t assume any obligation to replace or revise any forward-looking assertion, whether or not on account of new info, future occasions, or another motive. Extra info regarding dangers and uncertainties affecting the enterprise and different components that might trigger precise outcomes to vary materially from any forward-looking assertion is contained within the Firm’s Annual Report. This press launch doesn’t represent a proposal or invitation for the sale or buy of securities or property of Oxurion in any jurisdiction. No securities of Oxurion could also be provided or bought inside the US with out registration beneath the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any relevant U.S. state securities legal guidelines.
For additional info please contact:
Oxurion NVPascal GhosonChief Govt [email protected] | Backstage CommunicationJurgen [email protected] |
____
1. Article 14, first paragraph, of the Legislation of two Might 2007 on disclosure of main holdings. ANNEX 1
ANNEX 2
Supply: Oxurion NV